Predicting prostate cancer many years before diagnosis: how and why?

Predicting prostate cancer many years before diagnosis: how and why?

Evidence of reduced prostate cancer mortality from randomized trials in Europe supports early detection of prostate cancer with prostate-specific antigen (PSA). Yet PSA screening has generated considerable controversy: it is far from clear that the benefits outweigh risks, in terms of overdiagnosis...

Descripció completa

Dades bibliogràfiques
Autors principals:	Vickers, A, Lilja, H
Format:	Journal article
Idioma:	English
Publicat:	2012

Ítems similars

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
per: Lilja, H, et al.
Publicat: (2007)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
per: Lilja, H, et al.
Publicat: (2008)

We need a better marker for prostate cancer. How about renaming PSA?
per: Vickers, A, et al.
Publicat: (2012)

Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
per: Ulmert, D, et al.
Publicat: (2008)

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.
per: Lilja, H, et al.
Publicat: (2011)

Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring (Corrigendum) (Nature Reviews Cancer (2008) 8, (268-278))
per: Lilja, H, et al.
Publicat: (2008)

Urological cancer: Time for another rethink on prostate cancer screening.
per: Vickers, A, et al.
Publicat: (2012)

Prostate cancer: estimating the benefits of PSA screening.
per: Vickers, A, et al.
Publicat: (2009)

Screening for prostate cancer.
per: Carlsson, S, et al.
Publicat: (2012)

Screening for prostate cancer: To the editor
per: Carlsson, S, et al.
Publicat: (2012)

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study.
per: Ulmert, D, et al.
Publicat: (2008)

Screening for prostate cancer: early detection or overdetection?
per: Vickers, A, et al.
Publicat: (2012)

Five genetic variants associated with prostate cancer.
per: Vickers, A, et al.
Publicat: (2008)

The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.
per: Vickers, A, et al.
Publicat: (2007)

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study
per: Berglund Göran, et al.
Publicat: (2008-02-01)

How many patients with negative MRI have prostate cancer?
per: V. V. Hvorov, et al.
Publicat: (2018-12-01)

Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.
per: Haese, A, et al.
Publicat: (2004)

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
per: Vickers, A, et al.
Publicat: (2011)

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.
per: Vickers, A, et al.
Publicat: (2009)

Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer.
per: Botchorishvili, G, et al.
Publicat: (2009)

Why worry about how many species and their loss?
per: May, R
Publicat: (2011)

Why worry about how many species and their loss?
per: Robert M May
Publicat: (2011-08-01)

How Many Kinds of Birds Are There and Why Does It Matter?
per: George F Barrowclough, et al.
Publicat: (2016-01-01)

Imaging of prostate cancer local recurrences: why and how?
per: Adilson Prando
Publicat: (2010-06-01)

Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated?
per: Vickers, A, et al.
Publicat: (2010)

How many more deaths before they leave Iraq?
per: Abd Razak, Dzulkifli
Publicat: (2004)

How many oral antidiabetic drugs before insulin?
per: Jayant Kelwade, et al.
Publicat: (2017-01-01)

The continuing role of prostate-specific antigen as a marker for localized prostate cancer: 'do not throw the baby out with the bath water'.
per: Challacombe, B, et al.
Publicat: (2009)

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
per: Vickers, A, et al.
Publicat: (2010)

Prostate cancer polygenic risk score and prediction of lethal prostate cancer
per: Robert J. Klein, et al.
Publicat: (2022-04-01)

Tumor markers in prostate cancer I: blood-based markers.
per: Shariat, S, et al.
Publicat: (2011)

A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.
per: Vickers, A, et al.
Publicat: (2011)

A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
per: Vickers, A, et al.
Publicat: (2010)

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.
per: Savage, C, et al.
Publicat: (2010)

Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
per: Steuber, T, et al.
Publicat: (2007)

Youth Entrepreneurship in Germany: Empirical Evidence on the How, the Why, the How Many, the Who and the When
per: Rolf Sternberg, et al.
Publicat: (2023-06-01)

Quality of Preventive Care Before and After Prostate Cancer Diagnosis
per: Lauren Wallner, et al.
Publicat: (2017-01-01)

A CONSTITUTION OF MANY MINDS: WHY THE FOUNDING DOCUMENT DOESN'T MEAN WHAT IT MEANT BEFORE
per: Barber, N
Publicat: (2010)

A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France.
per: Benchikh, A, et al.
Publicat: (2010)

Testing new PSA subforms to enhance the accuracy of predicting cancer risk and disease outcome in prostate cancer.
per: Lilja, H
Publicat: (2008)